SGMT (Sagimet Biosciences Inc. Series A) stock: $10.96, $675.0M market cap, $240.1M cash, $434.9M EV, $792.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$10.96
Market cap
$675.0M
Cash
$240.1M
Enterprise value
$434.9M
Balance sheet
Cash
$240.1M
Debt
$0.0M
Net cash
$240.1M
Enterprise value
$434.9M
Basic shares
53.1M shares
Fully diluted shares
72.3M shares
Fully diluted market cap
$792.3M
Cash per share
$4.52
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading SGMT daily closes…
Loading price history…
Pipeline assets
Denifanstat
Phase 2 · ActiveModality: small molecule
Aliases ASC-40
Target FASN
Partnerships Ascletis: license partner (denifanstat designated ASC-40 in China; FASCINATE-1 China cohort). TAPI: license to resmetirom API IP for Sagimet's evaluation/manufacture of the denifanstat + resmetirom combination
Indications
Non-cirrhotic MASH with F2-F3 fibrosis(Phase 2)
F4-stage (cirrhotic) MASH (combination with resmetirom)(Stage not disclosed)
Acne(Stage not disclosed)
FASN-dependent solid tumors(Stage not disclosed)
Status note Oral once-daily FASN inhibitor. FDA granted Breakthrough Therapy designation for non-cirrhotic MASH with F2-F3 fibrosis (supported by the Phase 2b FASCINATE-2 trial). Developing a combination of denifanstat and resmetirom (Rezdiffra) for F4 cirrhotic MASH; also evaluating FASN inhibitors in acne and FASN-dependent solid tumors.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.